Active, not recruitingPhase 2NCT05856448
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus
Studying Systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Galapagos NV
- Principal Investigator
- Galapagos Study DirectorGalapagos NV
- Intervention
- GLPG3667(drug)
- Enrollment
- 186 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- University of Arizona College of Medicine - Tucson, Tucson, Arizona, United States
- University of California San Diego, La Jolla, California, United States
- Desert Medical Advances, Rancho Mirage, California, United States
- Millennium Clinical Trials, Simi Valley, California, United States
- Inland Rheumatology Clinical Trials, Upland, California, United States
- Upland Rheumatology Center, Upland, California, United States
- Arthritis & Rheumatic Disease Specialties, Aventura, Florida, United States
- Omega Research DeBary, DeBary, Florida, United States
- Alloy Clinical Research, LLC, Kissimmee, Florida, United States
- San Marcus Research Clinic, Miami, Florida, United States
- Advanced Pharma - Miami, Miami, Florida, United States
- Professional Research Center, Miami, Florida, United States
- Integral Rheumatology & Immunology Specialists, Plantation, Florida, United States
- Alliance Clinical Research of Tampa, Tampa, Florida, United States
- Albuquerque Clinical Trials, Albuquerque, New Mexico, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05856448 on ClinicalTrials.govOther trials for Systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07107659Safety and Efficacy of ONT01 in LupusHospital for Special Surgery, New York
- RECRUITINGNANCT07558850Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune DiseasesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGNCT06948110Deciphering the Genetic Architecture of Autoimmune DiseasesNational Human Genome Research Institute (NHGRI)
- RECRUITINGPHASE2NCT07409181A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Boehringer Ingelheim
- RECRUITINGPHASE3NCT07332481A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseEMD Serono Research & Development Institute, Inc.
- RECRUITINGEARLY PHASE1NCT07526350MTS109 in Patients With Refractory Autoimmune DiseasesShanghai Changzheng Hospital
- RECRUITINGEARLY PHASE1NCT07490041Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic DiseasesThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNANCT07470151Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology